# Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

> **NCT03707457** · PHASE1 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 3 (actual)

## Conditions studied

- Glioblastoma
- Glioblastoma Multiforme

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Anti-GITR Monoclonal Antibody MK-4166
- **DRUG:** IDO1 inhibitor INCB024360
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03707457
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-22
- **Primary completion:** 2019-11-30
- **Final completion:** 2020-06-18
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Funding/material support withdrawn
- **Last updated:** 2020-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03707457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03707457, "Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03707457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*